FRAUNHOFER INSTITUTE FOR MANUFACTURING ENGINEERING AND AUTOMATION IPA Background Individualized cancer therapy, as part of personalized medicine, aims for an optimal treatment with minimal side effects. In che- motherapy, one approach is to screen for the most potent combination of chemothe- rapeutics. The fully automated DiagnoSYS platform technology is a system effectively using the potential of chemosensitivity assays. Our Service The DiagnoSYS platform technology uses an ATP/TCA assay to determine chemo- sensitivity. Integrated tissue preparation combined with magnetic cell enrichment and depletion and luminescence based cell vitality measurements make it possible to screen for a high number of chemothera- peutic combinations. If you are looking for high efficient perso- nalized screening devices, we can offer you a full engineering service from planning to installation. Your Benefit The platform technology is based on the internationally accepted SBS-format. Therefore, all processing steps, from tissue preparation to luminescence or fluore- scence readings, can rapidly and easily be exchanged, and allows for processing different assay approaches. AUTOMATED PERSONALIZED CHEMOSENSITIVITY TESTING 1 DiagnoSYS device for chemosen- sitivity testing 2 Integrated tissue preparation Project Group for Automation in Medicine and Biotechnology Theodor-Kutzer-Ufer 1-3 | House 8 68167 Mannheim | Germany Contact Christian Reis Head of Bioprocess Engineering Phone +49 (0) 621 17207 120 [email protected] http://pamb.ipa.fraunhofer.de 1 2
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
F r a u n h o F e r I n s t I t u t e F o r M a n u F a c t u r I n g e n g I n e e r I n g a n d a u t o M a t I o n I P a
Background
Individualized cancer therapy, as part of
personalized medicine, aims for an optimal
treatment with minimal side effects. In che-
motherapy, one approach is to screen for
the most potent combination of chemothe-
rapeutics. The fully automated DiagnoSYS
platform technology is a system effectively
using the potential of chemosensitivity
assays.
our service
The DiagnoSYS platform technology uses
an ATP/TCA assay to determine chemo-
sensitivity. Integrated tissue preparation
combined with magnetic cell enrichment
and depletion and luminescence based cell
vitality measurements make it possible to
screen for a high number of chemothera-
peutic combinations.
If you are looking for high efficient perso-
nalized screening devices, we can offer you
a full engineering service from planning to
installation.
Your Benefit
The platform technology is based on
the internationally accepted SBS-format.
Therefore, all processing steps, from tissue
preparation to luminescence or fluore-
scence readings, can rapidly and easily
be exchanged, and allows for processing
different assay approaches.
AUTOMATED PERSONALIZED CHEMOSENSITIVITY TESTING
1 DiagnoSYS device for chemosen-
sitivity testing
2 Integrated tissue preparation
Project Group for Automation in
Medicine and Biotechnology
Theodor-Kutzer-Ufer 1-3 | House 8
68167 Mannheim | Germany
Contact
Christian Reis
Head of Bioprocess Engineering
Phone +49 (0) 621 17207 120
http://pamb.ipa.fraunhofer.de
1 2
Related Documents
